New pill takes on stomach cancer in first human trial
NCT ID NCT06056024
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shrink tumors. The study is now complete and no longer enrolling new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, KRAS MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Hospital
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, 05505, South Korea
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic-Arizona
Phoenix, Arizona, 85054, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
NCKUH
Tainan, 704, Taiwan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Seoul National University Bundang Hospital
Seongnam, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, 137-701, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 3706674 (a tablet that blocks growth signals in cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced stomach or esophageal cancer that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 47 participants, so it is not yet clear if the drug is effective or safe for a larger population. Side effects are unknown and the drug is being tested in humans for the first time.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.